Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Observational

Attitudes and Perceptions of Corresponding Authors From Top International Medical Journals Regarding the Use of Artificial Intelligence in the Scientific Process

NCT07326501 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-12-10
Last updated
2026-01-08

Condition(s) studied

Artificial IntelligenceBiomedical ResearchScientific PublishingSurveys and Questionnaires

Investigational drug(s) / intervention(s)

observational survey

observational survey: This is an observational, non-interventional study based on an anonymous online questionnaire. No intervention is administered to participants.

Study summary

"Artificial intelligence (AI), including large language models and conversational tools, is increasingly being used in medical research. These tools may assist researchers at different stages of the scientific process, such as generating research ideas, reviewing the literature, analyzing data, writing manuscripts, and preparing articles for publication. While interest in AI is growing rapidly, there is still limited information on how these tools are actually perceived and used by leading medical researchers. This study aims to better understand the attitudes, perceptions, and self-reported uses of artificial intelligence among corresponding authors who have published in six major international medical journals. These authors play a key role in shaping scientific standards and editorial practices, and their views are essential to understanding how AI may influence the future of medical research. Participants are invited to complete an anonymous online questionnaire that asks about their familiarity with AI tools, how and when they use or plan to use them in the research process, the potential benefits they perceive, and the concerns or limitations they identify. The survey also explores participants' expectations regarding transparency, ethical guidance, and journal policies related to the use of artificial intelligence in scientific work.The study is observational and does not involve any medical intervention or collection of personal or health-related data. Participation is voluntary, and responses are fully anonymous.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Participants without any disease, condition, or related symptoms are permitted to participate. This study is a non-clinical, observational survey focusing on attitudes and practices related to artificial intelligence in scientific research, not on health conditions. Exclusion Criteria: * Authors who are not corresponding authors. * Students, residents, interns, or trainees without corresponding author status. * Individuals not involved in biomedical or medical research activities. * Individuals who decline to participate or do not complete the online questionnaire.

Primary outcome measure(s)

  • Self-reported attitudes regarding the use of artificial intelligence in the scientific research process — At the inclusion
    Participants report their attitudes and perceptions regarding the use of artificial intelligence in the scientific research process through multiple-choice and Likert-scale items. Responses are analyzed descriptively; higher scores indicate more favorable attitudes toward the use of artificial intelligence.
  • Perceptions regarding the use of artificial intelligence in the scientific research process — At the inclusion
    Participants report their attitudes and perceptions regarding the use of artificial intelligence in the scientific research process through multiple-choice and Likert-scale items. Responses are analyzed descriptively; higher scores indicate more favorable attitudes toward the use of artificial intelligence.

Trial sites (1)

FacilityCityRegionStatus
CHU de NICE Nice Alpes Maritimes
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07326501 on ClinicalTrials.gov ↗ ← All trials in France